Intellia Therapeutics (NTLA) Current Assets (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Current Assets of $466.4 million for Q1 2026, down 15.41% year-over-year from $551.4 million in Q1 2025, and down 11.61% quarter-over-quarter from $527.7 million in Q4 2025.
Intellia Therapeutics (NTLA) Current Assets (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Current Assets for 12 consecutive years, with $466.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 15.41% year-over-year to $466.4 million; the TTM figure through Mar 2026 stood at $466.4 million (down 15.41% YoY), while the FY2025 annual figure was $527.7 million, down 17.53% from the prior year.
- Current Assets declined to $466.4 million in Q1 2026 per NTLA's latest filing, from $527.7 million in the prior quarter.
- Across five years, Current Assets topped out at $1.2 billion in Q4 2022 and bottomed at $466.4 million in Q1 2026.
- Historically, Current Assets has averaged $779.8 million across 5 years, with a median of $858.9 million in 2022.
- Annual changes were most pronounced in 2022 — Current Assets jumped 62.98% — and 2025, when it slumped 37.63%.
- Intellia Therapeutics' Current Assets stood at $1.2 billion in 2022, then dropped by 17.95% to $998.3 million in 2023, then plunged by 35.91% to $639.9 million in 2024, then declined by 17.53% to $527.7 million in 2025, then retreated by 11.61% to $466.4 million in 2026.
- Business Quant data shows NTLA's Current Assets at $466.4 million in Q1 2026, $527.7 million in Q4 2025, and $581.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 527.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 527.83 Mn |
| Mar 31, 2026 | 466.45 Mn |
| Dec 31, 2025 | 527.71 Mn |
| Sep 30, 2025 | 581.94 Mn |
| Jun 30, 2025 | 495.95 Mn |
| Mar 31, 2025 | 551.39 Mn |
| Dec 31, 2024 | 639.86 Mn |
| Sep 30, 2024 | 710.90 Mn |
| Jun 30, 2024 | 757.21 Mn |
| Mar 31, 2024 | 884.04 Mn |
| Dec 31, 2023 | 998.33 Mn |
| Sep 30, 2023 | 893.49 Mn |
| Jun 30, 2023 | 939.62 Mn |
| Mar 31, 2023 | 963.67 Mn |
| Dec 31, 2022 | 1.22 Bn |
| Sep 30, 2022 | 858.95 Mn |
| Jun 30, 2022 | 895.43 Mn |
| Mar 31, 2022 | 875.37 Mn |
| Dec 31, 2021 | 769.30 Mn |
| Sep 30, 2021 | 814.77 Mn |